Loading clinical trials...

Safety and Efficacy of BFH772 in Psoriasis Patients | Clinical Trials | Clareo Health

COMPLETEDPHASE1/PHASE2

Safety and Efficacy of BFH772 in Psoriasis Patients

A Proof of Concept Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Topical Administrations of BFH772 in Patients With Psoriasis.

NCT00987870•Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

This study will determine the efficacy of topical BFH772 in psoriasis patients and the safety after multiple dosing.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Stable mild to moderate plaque psoriasis (BSA involvement \< 10% or PASI \< 10
•Category "mild to moderate" on PGA as according to the EMEA (CHMP 2004) (Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis), with or without arthritis
•Diagnosed or history of psoriasis for at least 6 months prior to screening

Exclusion Criteria

•Nonplaque forms of psoriasis
•Drug-induced psoriasis
•Current use of beta blockers
•Congestive heart failure (NYHA \>III), QT interval \>450msec or poorly controlled diabetes mellitus

Locations (1)

Novartis Investigator Site

Berlin, Germany

Key Dates

Start Date

September 1, 2009

Primary Completion Date

February 1, 2010

Last Updated

March 28, 2011

Enrollment

ACTUAL participants

Conditions

PsoriasisArthritis

Interventions

BFH772

DRUG

Placebo

DRUG

BFH772

DRUG

Placebo

DRUG

calcipotriol/betamethasone

DRUG

A Study of Picankibart in Patients With Active Psoriatic Arthritis

NCT07295509

Psoriatic Arthritis

View study

RECRUITING

Natural History and Development of Spondyloarthritis

NCT01422694

ArthritisSpondylitis, Ankylosing

View study

RECRUITING

Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 28, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety and Efficacy of BFH772 in Psoriasis Patients

Inclusion Criteria

Exclusion Criteria

A Study of Picankibart in Patients With Active Psoriatic Arthritis

Natural History and Development of Spondyloarthritis

Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

Targeted Remotely-delivered Anti-inflammatory Interventions With Exercise for Rheumatoid Arthritis